Formycon AG (FRA:FYB)

Market Cap	455.74M
Revenue (ttm)	48.07M
Net Income (ttm)	-165.17M
Shares Out	n/a
EPS (ttm)	-9.35
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	25
Average Volume	432
Open	25.15
Previous Close	25.00
Day's Range	25.15 - 25.45
52-Week Range	18.62 - 63.70
Beta	n/a
RSI	58.64
Earnings Date	Mar 26, 2026

About Formycon AG

Formycon AG, a biotechnology company, develops biosimilar drugs in Germany and Switzerland. It provides ranibizumab and aflibercept used in the treatment of neovascular age-related macular degeneration, diabetic macular edema, choroidal neovascularization, proliferative diabetic retinopathy, and macular edema under the Ranivisio, Ongavia, Cimerli, Ranopto, Uptera, and Ravegza brand names, as well as AHZANTIVE, Baiama, and Fovlya brand names. The company’s pipeline includes ustekinumab used in the treatment of Crohn’s disease, ulcerative colitis...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1999
• Employees: 250
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: FYB